Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Lanopepden (Primary) ; Lanopepden (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 30 Jul 2013 Results published in the Journal of Clinical Pharmacology.
- 08 Jun 2012 New trial record